Given that MAML1 is a coregulator of STAT3, we believe that the induction of MAML1 also partially accounts for the constitutive activation of STAT3 in HCC and that targeting MAML1 with its inhibitor may overcome HCC progression by reducing STAT3 transcriptional activity. This evidence concerns the gene MAML1 and hepatocellular carcinoma.